Protein matrix vaccines and related methods of making and administering such vaccines

Patent metadata

Field	Value
Publication number	US-2016136257-A1
Application number	US-201514950113-A
Country	US
Kind code	A1
Filing date	Nov 24, 2015
Priority date	Aug 7, 2006
Publication date	May 19, 2016
Grant date	—

Abstract

The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration.

First claim

What is claimed is:

1 - 42 . (canceled)

43 . A method of eliciting an immune response in a subject against an infectious agent, said method comprising administering to a subject in an amount sufficient to induce the production of antibodies in said subject a vaccine composition comprising an antigen of interest and a carrier protein matrix, wherein (i) said carrier protein matrix comprises covalently cross-linked carrier protein molecules, (ii) no more than 50% of said antigen of interest is covalently cross-linked to said carrier protein molecules, and (iii) said antigen is entrapped with said carrier protein matrix to form a complex.

44 . The method of claim 43 , wherein said method comprises a second administering step wherein said vaccine composition is administered to said subject in an amount sufficient to boost the production of antibodies in said subject.

45 . The method of claim 44 , wherein said production of antibodies is T-cell dependent.

46 . The method of claim 43 , wherein said production of antibodies is sufficient to prevent or reduce infection of said subject by an infectious agent.

47 . The method of claim 43 , wherein said infectious agent is pneumococcus, meningococcus, Haemophilus influenzae type B, Pseudomonas aeruginosa, Francisella tularensis, Shigella species, Salmonella species, Acinetobacter species, Burkholderia species, and Escherichia coli.

48 . The method of claim 43 , wherein said method comprises a second administering step wherein a second vaccine composition comprising an antigen of interest is provided to said subject in an amount sufficient to boost the production of antibodies in said subject.

49 . The method of claim 48 , wherein said production of antibodies is sufficient to prevent or reduce infection of said subject by a second infectious agent.

50 . The method of claim 43 , wherein said antibodies are IgG antibodies.

51 . The method of claim 48 , wherein said antibodies are IgG antibodies.

52 . The method of claim 43 , wherein said subject is a human.

53 . The method of claim 43 , wherein said antigen of interest is a polysaccharide, a polyalcohol, or a poly amino acid.

54 . The method of claim 43 , wherein said antigen of interest comprises two or more antigens of interest.

55 . The method of claim 53 , wherein said polysaccharide comprises at least 18 residues.

56 . The method of claim 55 , wherein said polysaccharide is a Streptococcus pneumoniae polysaccharide, Francisella tularensis polysaccharide, Bacillus anthracis polysaccharide, Haemophilus influenzae polysaccharide, Salmonella typhi polysaccharide, Salmonella species polysaccharide, Shigella polysaccharide, or Neisseria meningitidis polysaccharide.

57 . The method of claim 56 , wherein said Streptococcus pneumoniae polysaccharide is capsular type 1, 2, 3, 4, 5, 6A, 6B, 7A, 7B, 7C, 7F, 8, 9A, 9L, 9N, 9V, 10A, 10B, 10F, 11A, 11B, 11C, 11D, 11F, 12A, 12B, 12F, 13, 14, 15A, 15B, 15C, 15F, 16A, 16F, 17A, 17F, 18A, 18B, 18C, 18F, 19A, 19B, 19C, 19F, 20, 21, 22F, 23B, 23F, 24A, 24B, 24F, 25A, 25F, 27, 28A, 28F, 29, 31, 32A, 32F, 33A, 33B, 33D, 33F, 34, 35A, 35B, 35F, 36, 37, 38, 39, 40, 41A, 41F, 42, 43, 44, 45, 46, 47A, 47F, or 48.

Assignees

• Harvard College

Inventors

• Mekalanos John J

Classifications

• A61K2039/645

  Dendrimers; Multiple antigen peptides · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61K39/0283

  Shigella · CPC title

• A61K39/0275

  Salmonella · CPC title